Direxion Daily Phrmctcl&MdclBl3XShrsETF (PILL)
10.55
+0.40 (+3.94%)
USD |
NYSEARCA |
May 20, 16:00
10.44
-0.11 (-1.04%)
After-Hours: 20:00
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.95% | -0.35% | 13.76M | 35200.67 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.08% | 115.0% | 6.756M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Prospectus Objective | Growth and Income |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 4.46 yrs |
| Tony Ng | 4.46 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
16
6.756M
-666.64M
Category Low
7.930B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of April 30, 2022
Performance Versus Category
As of May 20, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of May 20, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Dreyfus Government Secs Cash Mgmt Admin | 27.92% | 1.00 | 0.00% |
| Goldman Sachs FS Treasury Intms Instl | 16.75% | 1.00 | 0.00% |
| Goldman Sachs FS Government Instl | 10.71% | 1.00 | 0.00% |
| Merck & Co Inc | 3.37% | 93.55 | 1.59% |
| Viatris Inc | 3.35% | 11.80 | 0.94% |
| Bristol-Myers Squibb Co | 3.16% | 76.19 | 0.30% |
| Eli Lilly and Co | 3.08% | 298.85 | 4.39% |
| Royalty Pharma PLC Class A | 2.98% | 39.52 | -0.65% |
| Catalent Inc | 2.98% | 100.19 | 0.46% |
| Johnson & Johnson | 2.94% | 176.98 | 1.75% |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Pharmaceuticals Select Industry Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index and other financial instruments that provide daily leveraged exposure to the index or to ETFs that track the index. The index is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Prospectus Objective | Growth and Income |
| Fund Owner Firm Name | Direxion Funds |
| Prospectus Benchmark Index | |
| S&P Pharms Select Industry TR USD | 300.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Paul Brigandi | 4.46 yrs |
| Tony Ng | 4.46 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (5-20-22) | 0.08% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 17.36 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 19, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 11/15/2017 |
| Last Annual Report Date | 10/31/2021 |
| Last Prospectus Date | 2/28/2021 |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund |
|
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)